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ABSTRACTS
Background Although cancer immunotherapy is one of 
the most effective advanced- stage cancer therapies, no 
clinically approved cancer immunotherapies currently exist 
for colorectal cancer (CRC). Recently, programmed cell death 
protein 1 (PD-1) blockade has exhibited clinical benefits 
according to ongoing clinical trials. However, ongoing clinical 
trials for cancer immunotherapies are focused on PD-1 
signaling inhibitors such as pembrolizumab, nivolumab, and 
atezolizumab. In this study, we focused on revealing the 
distinct response mechanism for the potent CD73 ectoenzyme 
selective inhibitor AB680 as a promising drug candidate that 
functions by blocking tumorigenic ATP/adenosine signaling in 
comparison to current therapeutics that block PD-1 to assess 
the value of this drug as a novel immunotherapy for CRC.
Methods To understand the distinct mechanism of AB680 in 
comparison to that of a neutralizing antibody against murine 
PD-1 used as a PD-1 blocker, we performed single- cell RNA 
sequencing of CD45+ tumor- infiltrating lymphocytes from 
untreated controls (n=3) and from AB680- treated (n=3) and 
PD-1- blockade- treated murine CRC in vivo models. We also 
used flow cytometry, Azoxymethane (AOM)/Dextran Sulfate 
Sodium (DSS) models, and in vitro functional assays to 
validate our new findings.
Results We initially observed that the expressions of Nt5e 
(a gene for CD73) and Entpd1 (a gene for CD39) affect T cell 
receptor (TCR) diversity and transcriptional profiles of T cells, 
thus suggesting their critical roles in T cell exhaustion within 
tumor. Importantly, PD-1 blockade significantly increased the 
TCR diversity of Entpd1- negative T cells and Pdcd1- positive 
T cells. Additionally, we determined that AB680 improved the 
anticancer functions of immunosuppressed cells such as Treg 
and exhausted T cells, while the PD-1 blocker quantitatively 
reduced Malat1high Treg and M2 macrophages. We also 
verified that PD-1 blockade induced Treg depletion in AOM/
DSS CRC in vivo models, and we confirmed that AB680 
treatment caused increased activation of CD8+ T cells using 
an in vitro T cell assay.
Conclusions The intratumoral immunomodulation of 
CD73 inhibition is distinct from PD-1 inhibition and exhibits 
potential as a novel anticancer immunotherapy for CRC, 
possibly through a synergistic effect when combined with 
PD-1 blocker treatments. This study may contribute to 
the ongoing development of anticancer immunotherapies 
targeting refractory CRC.
BACKGROUND
Cancer immunotherapy has generated 
unparalleled and durable responses in 
regard to several cancers and is a pillar of 
advanced- stage cancer therapy.1 Colorectal 
cancer (CRC) is one of the most prominent 
causes of cancer- related deaths and exhibits 
high rates of morbidity and mortality.2 Recent 
clinical trials examining the use of immune 
checkpoint inhibitors (ICIs) are anticipated 
to improve survival rates in CRC.3 4 Never-
theless, no clinically approved ICI for the 
treatment of CRC exists currently. Ongoing 
clinical trials examining cancer immunother-
apies are focused on programmed cell death 
protein 1 (PD-1) signaling inhibitors such 
as pembrolizumab, nivolumab, and atezoli-
zumab.3 5–7 To extend the beneficial effects 
of cancer immunotherapy to more patients, 
ongoing efforts are aimed at developing new 
target- based cancer immunotherapeutic 
drugs. Adenosine signaling has emerged as a 
key metabolic pathway that regulates tumor 
immunity.8–10 CD73 (also known as Nt5e 
or ecto-5- nucleotidase) is a novel immune 
checkpoint enzyme that plays a key role in 
tumor growth and metastasis.11 This enzyme 
converts extracellular ATP to immunosup-
pressive adenosine in concert with CD39 (also 
known as Entpd1). Specifically, most tumors 
and their adjacent tissue microenvironment 
harness the CD73- mediated adenosynergic 
mechanism for immune surveillance escape. 
In this study, we investigated the distinct 
response mechanism of the potent and selec-
tive CD73 inhibitor AB680 that is currently 
undergoing phase I clinical trials.12 13 We 
revealed that AB680 and PD-1 blockers can 
differentially reshape intratumoral immune 
profiles according to the results of full- scale 
immune profiles generated using single- cell 
RNA sequencing (scRNA- seq). Based on 
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recent technical progress, scRNA- seq has gained wide-
spread use due to its ability to measure diversity or hetero-
geneous populations of immune cells.14 This approach 
exhibits excellent potential for identifying new cellular 
and molecular factors that function in response to ICIs. 
This is the first report to compare the results of scRNA- seq 
analysis of CD73- inhibitor and PD-1- blocker- treated 
tumors, and our results provide novel insights into the 
response mechanism activated by the CD73 inhibitor and 
indicate that this mechanism is distinct from that acti-
vated by the PD-1 blocker.
MATERIALS AND METHODS
Animal studies
For tumor- bearing models, BALB/c mice were purchased 
from Dooyeol Biotech (Daejeon, Republic of Korea). We 
used 6- week to 8- week- old male mice that were housed in 
a pathogen- free animal facility. All animal experiments 
were approved by the Institutional Animal Use and Care 
Committee of the Korea Research Institute of Chemical 
Technology and performed in accordance with the Guide 
for the Care and Use of Laboratory Animals published by 
the US National Institutes of Health. Tumor- bearing models 
were established by subcutaneous injection of 1×106 CT26 
cells (ATCC CRL-2638; ATCC, Manassas, Virginia, USA) into 
the right flanks of mice. Five days after inoculation, the mice 
were randomly separated into control, AB680- treated, and 
PD-1 blocker- treated groups. The CD73 inhibitor AB680 
(20 mg/kg) (MedChemExpress, Monmouth Junction, New 
Jersey, USA) was administered from day 0 to day 15 after initi-
ation via the intraperitoneal route. A PD-1 blocking antibody 
(6 mg/kg) (BioLegend, San Diego, California, USA) was 
administered intravenously every 3 days from day 0 onward 
into the tail vein. Tumors were measured every 3 days using 
calipers, and their volumes were calculated according to 
the following formula: volume (mm3)=(d2×D)/2, where d 
and D represent the shortest and longest tumor diameters, 
respectively.
AOM-DSS murine model
All animal experiments were approved by the Institutional 
Animal Use and Care Committee of the Korea Research 
Institute of Chemical Technology and performed in 
accordance with the Guide for the Care and Use of Labo-
ratory Animals published by the US National Institutes of 
Health. A colitis- associated cancer model mouse was made 
by intraperitoneal injection of 10 mg/kg azoxymethane 
(AOM) (Sigma- Aldrich, St. Louis, Missouri, USA) and 
by oral administration of 2.5% Dextran Sulfate Sodium 
(DSS) with a molecular weight of 36,000–50,000 (MP 
Biomedicals, Santa Ana, California, USA). Five- week- old 
male C57BL/6J mice (Dooyeol Biotech) were acclima-
tized for the first week. At 6 weeks of age, mice were 
randomly divided into a control healthy group (n = 8), 
AOM/DSS group (n = 8) and AOM/DSS+AB680 or PD-1 
blockade- treated group (n = 8). Seven days after AOM 
injection, 2.5% DSS was given in the drinking water over 
7 days, followed by 14 days of regular water. Three cycles 
of DSS treatment were repeated. AB680 (10 mg/kg) 
(MedChemExpress) was administered from day 0 to day 
21 after the end of third cycle of DSS treatment via the 
intraperitoneal route. A PD-1 blocking antibody (6 mg/
kg) (BioLegend, San Diego, California, USA) was admin-
istered intravenously every 3 days from day 0 to 21 after 
the end of third cycle of DSS treatment in the tail vein. All 
mice were sacrificed at the end of the experiments, and 
the colon were obtained. Each colon was cut open longi-
tudinally, and the normal tissue of the proximal colon, 
dysplasia tissue of the middle colon and cancer tissue of 
the distal colon were distinguished and assessed using a 
stereoscopic microscope. For flow cytometry analysis, we 
generated cell suspension of minced colon tissues using 
an Intestine Dissociation Kit (Miltenyi Biotec, Bergisch 
Gladbach, Germany) following the manufacturer’s 
protocol.
Cell sorting
The whole tumor was harvested from a sacrificed mouse 
and placed into 10 mL ice- cold Dulbecco’s phosphate- 
buffered saline (PBS) in a 50 mL falcon tube, and the 
CT26 tumor tissue (tumor size is ~3–4 mm) was then cut 
and minced thoroughly with a scalpel for 1–2 min into 
fragments that were approximately 0.5 mm and smaller. 
We generated cell suspensions of minced tumors using a 
Tumor Dissociation Kit (Miltenyi Biotec, Bergisch Glad-
bach, Germany) following the manufacturer’s protocol. 
Cell suspensions were stained with anti- mouse CD45 
monoclonal antibodies (BD Biosciences, Franklin Lakes, 
New Jersey, USA), washed, and then resuspended in PBS 
containing Hank’s balanced salt solution supplemented 
with 4% fetal bovine serum (Gibco). CD45- positive tumor- 
infiltrating lymphocytes (TILs) were isolated to almost 
100% purity using an Aria cytometer (BD Biosciences).
Human peripheral blood collection and in vitro T cell 
proliferation assay
Peripheral blood from healthy donors was obtained 
from the Red Cross Blood Center (Daejeon, Republic of 
Korea) according to established guidelines. The methods 
and protocols used in this study were approved by the 
Institutional Review Board of the Red Cross, and written 
informed consent for study participation was obtained 
from donors. Donor information was not disclosed. For 
the T cell proliferation assay, human T cells were isolated 
at >95% purity from peripheral blood based on negative 
selection using the RosetteSep Human T Cell Enrich-
ment Cocktail (STEMCELL Technologies, Vancouver, 
Canada). Isolated human T cells were labeled with various 
concentrations of Carboxyfluorescein succinimidyl 
ester (CFSE) (Invitrogen, USA) at 37°C for 15 min. The 
labeled cells were collected, washed with fresh medium, 
counted, seeded in 96- well plates (1×105 cells/well), and 
stimulated with magnetic beads coated with anti- CD3 
and anti- CD28 antibodies (Invitrogen) at a 1:1 cell:bead 
ratio. After 96 hours, the cells were collected and stained 
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with 7- AAD (20 min at room temperature). Samples of 
unlabelled and stimulated cells were stained with anti- 
CD45- APC mAb (BD Biosciences) and anti- IFNγ-PE 
mAb (BD Biosciences). Immediately after this step, the 
cells were analyzed using a flow cytometer (MACSQuant 
Analyzer VYB, Miltenyi Biotec).
Antibodies and flow cytometry
For the fluorescence- activated cell sorting (FACS) anal-
ysis, we stained cells with anti- mouse CD45, CD3, CD4, 
CD8, CD25, F4/80, CD11b, Ly6c, PD-1, CD73, CD39- 
monoclonal antibodies, 7ADD, and Annexin V (BD 
Biosciences) following the manufacturer’s protocol.
The cells were incubated on ice for 20 min, washed with 
chilled Annexin V binding buffer, and analyzed. Staining 
data were collected using a MACSQuant Analyzer VYB 
(Miltenyi Biotec, Bergisch Gladbach, Germany).
Single- cell library preparation and sequencing scRNA- seq 
libraries from three untreated control TILs (C1–C3), 
three CD73 inhibitor- treated TILs (KM1–KM3), and three 
PD-1 blockade- treated TILs (PD1-1–PD1-3) were prepared 
using Chromium Single Cell 3 Reagent Kits (v2) that were 
comprised of a Single Cell 3 Library & Gel Bead Kit v2 
(PN-120237), a Single Cell 3 Chip Kit v2 (PN-120236), and 
an i7 Multiplex Kit (PN-120262) (10x Genomics) according 
to the Single Cell 3 Reagent Kits (v2) User Guide. Libraries 
were sequenced on an Illumina HiSeq X Ten System with 
150 bp paired- end reads and one sample per lane.
Preprocessing of scRNA-seq data
The sequencing data produced by droplet- based scRNA- seq15 
were demultiplexed and converted to FASTQ format using 
Illumina bcl2fastq software. The Cell Ranger Single- Cell 
Software Suite (V.3.0.2) was used to perform sample demulti-
plexing, barcode processing and single- cell 3 gene counting. 
The cDNA insert was aligned with the GRCh38 reference 
genome. Further analyses, including quality control, iden-
tification of highly variable genes, dimensionality reduc-
tion, standard unsupervised clustering algorithms, and the 
discovery of differentially expressed genes (DEGs), were 
performed using the Seurat package in R (V.3.1.4).16 We 
visually inspected the distributions and determined the 
thresholds for all samples as described by Plasschaert et 
al.17 We discarded low- quality cells with log10 (total feature 
count)≤2.5 or that exhibited a proportion of mitochondrial 
gene expression ≥20. We also used Scrublet18 to exclude cells 
that were predicted to be doublets.
Clustering analysis
We used the FindVariableFeatures in the Seurat package to 
identify highly variable genes and then performed principal 
component analysis with the top 2000 variable genes. Clus-
ters were partitioned with FindClusters in the Seurat package, 
and cells were projected into a two- dimensional space with 
uniform manifold approximation and projection (UMAP). 
DEGs in each cluster were identified using FindMarkers in the 
Seurat package. We also used the SingleR19 method.
DEG analysis of pseudo-bulk profiles from scRNA-seq
To exclude potential bias due to the different cell counts 
of each individual in a given cluster or a group of clus-
ters, we calculated the sum of the UMI counts across all 
cells from each sample to generate pseudo- bulk profiles. 
DEGs were identified using the DESeq2 package in R 
(V.1.26.0)20 based on the average expression level (mean 
CPM) in each individual. DEGs with a p value <0.05 and 
|log2(FC: fold change)|>1 were used for Gene Ontology 
(GO) functional enrichment analysis with the Database 
for Annotation, Visualization and Integrated Discovery 
(DAVID) website.21 22
Trajectory analysis
Single- cell trajectory analysis was performed using the 
Monocle2 package (V.2.14.0).23 To chronically sort cells 
by pseudo- time using the orderCells in Monocle2, we 
selected the top 1000 DEGs identified by the FindAll-
Markers in the Seurat package. To visualize and interpret 
the results using the plot_cell_trajectory in Monocle2, the 
dimension was reduced using the DDRTree method.
Cellular interaction analysis
Cell–cell interaction analysis was conducted using Cell-
PhoneDB,24 a public repository of interactions between 
ligands and receptors. We used the CellphoneDB Python 
package (V.2.1.2) for the analysis, and the single- cell 
expression data of hematopoietic stem cells (HSCs), T 
cells, and myeloid cells from all samples were used as the 
input.
Kaplan-Meier analysis
We used Gene Expression Profiling Interactive Analysis 
(GEPIA),25 which is an interactive web server for analysis 
of RNA sequencing data including 9736 tumors and 8587 
normal samples from The Cancer Genome Atlas (TCGA) 
and the Genotype- Tissue Expression (GTEx) project, to 
perform survival analysis based on gene expression levels. 
We generated Kaplan- Meier plots to assess prognostic 
values of NT5E, ENTPD1 and PDCD1 expression in 
patients with colon adenocarcinoma. The patients were 
classified into high and low expression groups using the 
median expression of genes as the cut- off value.
Statistical analysis
All statistical tests were performed on directed pairwise 
comparisons. Unpaired t- tests were performed to analyze 
differences between two groups. Significance is displayed 
as *p<0.05; **p<0.01; ***p<0.001. Statistical analyses were 
done using Prism (GraphPad, La Jolla, California, USA).
RESULTS
scRNA-seq of AB680-treated, PD-1 blocking antibody-treated, 
and untreated TILs to characterize cellular composition and 
lineage
To understand the mode of action of the potent and 
selective CD73 inhibitor AB680, we used CT26, an ICI- 
responsive CRC- cell- line- bearing in vivo mouse model, 
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to investigate whole- scale cellular diversity and tran-
scriptional profile changes in TILs through the use of 
scRNA- seq (figure 1A). To depict the baseline cellular 
composition, lineage, and interaction of TILs from 
tumors with or without AB680 or PD-1 blocker treatment, 
we sorted and profiled CD45+ TILs from each tumors of 
the control (n=3), AB680 (n=3) and PD-1 blocker groups 
(n=3) using droplet- based scRNA- seq (figure 1A). We 
also performed flow cytometry analysis of TILs to confirm 
our scRNA- seq results (figure 1A). Notably, AB680 and 
the PD-1 blocker both exhibited potent tumor growth 
inhibition activity compared with that of the control 
(figure 1B,C). We also demonstrated that combined 
treatment utilizing AB680 and the PD-1 blocker could 
additively reduce tumor growth in comparison to that 
achieved using each individual treatment (figure 1B,C). 
As a result, a total of 75,373 cells were retained, and these 
included 24,784 from control, 29,463 from the AB680- 
treated group, and 21,126 from the PD-1 blocker- treated 
group (online supplemental table 1). Subsequently, we 
performed unsupervised clustering analysis and used 
UMAP26 to visualize the cells and cellular proportions 
according to cell type (figure 1D). Notably, myeloid 
cells were more abundant than were T cells, B cells, and 
natural killer (NK) cells (figure 1D,E). We classified our 
clusters into five broad cellular lineages (myeloid cells, 
granulocytes, T cells, NK cells, and B cells) by combining 
the results of the singleR package and the expression 
profiles of cell type- specific marker genes (figure 1D,F). 
Most cellular lineages were not significantly different 
between the control and treated groups, with the excep-
tion of myeloid cells (figure 1G).
Reclustering analysis of T cells revealed differential cellular 
proportions among AB680 and PD-1 blocker-treated and 
control TILs: depletion of intratumoral MALAT1+ Treg cells and 
CD4+ exhausted T cells was observed in PD-1 blocker treated 
TILs, but not in AB680 blocker-treated TILs.
Although the total numbers of T cells were not signifi-
cantly different among the control, AB680, and PD-1 
blocker- treated groups (figure 1H), reclustering analyses 
of T cells identified 12 T cell subclusters that included 
six CD8+ exhausted (CD8+ Tex) T cells (C0, C1, C5, C6, 
C8, and C10), one CD8+ effector T cell (C9), one CD8+ 
effector memory (CD8+ Tem) T cell (C7), two CD4+ regu-
latory T (Treg) cells (C2, C4), one CD4+ helper T cell 
(C3), and one CD4+ Tex (C11) that exhibited differential 
distribution (figure 2A,B). We identified subclusters of 
T cells possessing the expression pattern of major T- cell 
lineage markers (figure 2C). Specifically, we also identi-
fied the expression patterns of important genes that can 
be used for identifying T cell subclusters (figure 2D). 
Importantly, the majority of CD8+ T cells (six subclus-
ters: C0, C1, C6, C7, C8, and C10) from all eight clus-
ters of CD8+ T cells exhibited exhausted phenotypes that 
expressed high levels of Havcr2, Lag3, Ctla4, and Tigit 
(figure 2D). High expression of effector molecules such 
as Gzmb, Ifng, and Cx3cr1 in exhausted CD8+ T cells 
(Tex) was also noted (figure 2D). Although the diversity 
of the T- cell subclusters was similar among the controls 
and the two treated groups (figure 2E), we observed that 
CD8+ effector T cells (C9) were significantly upregulated 
in the PD-1 blocker- treated group compared with that 
in the control group. The AB680- treated CD8+ effector 
T cells (C9) were also similarly increased; however, the 
increase was not significant (figure 2F). No significant 
proportional changes were observed among the controls 
and the two treated groups in regard to Cx3cr1high CD8+ 
Tex cells and Cxcr3high CD8+ effector memory T cells 
(C7) (figure 2F). Regarding proportional changes in 
CD4+ T cells, we observed that one (C2) of the two Treg 
subclusters and the Ikzf2high CD4+ Tex cells (C11) were 
significantly reduced in the PD-1 blocker- treated group 
compared with that in the control; however, this was not 
observed in the AB680- treated group (figure 2F). Lastly, 
we analyzed proportions of CD8+ T cells to CD4+ T cells 
from TILs of CT26 tumor- bearing mice through FACS 
analysis to confirm the result of those proportions from 
our scRNA- seq results (online supplemental figure 1a- c). 
Although proportions of CD8+ T cells to CD4+ T cells did 
not show significant difference among the control, AB680, 
and PD-1 blocker- treated groups from our scRNA- seq 
results (online supplemental figure 1a), AB680 treat-
ment showed a trend to increase ratio of CD8+ T cells to 
CD4+ T cells compared with the control group. Thus, we 
evaluate the effect of AB680 on proportions of CD8+ T 
cells to CD4+ T cells through FACS analysis of TILs from 
eight mice per control, AB680, and PD-1 blocker- treated 
groups (online supplemental figure 1b,c). As shown in 
online supplemental figure 1c, ratios of CD8+ T cells to 
CD4+ T cells were significantly increased by treatment of 
AB680, and PD-1 blocker compared with control.
PD-1 blockade resulted in increased T-cell receptor (TCR) 
diversity of Entpd1-negative T cells
The ectoenzymes CD73 and CD39 increase the concen-
tration of extracellular adenosine in the microenviron-
ment in proximity to these enzyme- expressing cells.11 27 28 
Thus, it is important to analyze the cellular and molecular 
differences between Nt5e- positive and Entpd1- positive 
and Nt5e- negative and Entpd1- negative cells. Increased 
TCR diversities as assessed by the number of unique 
CDR3 regions of each individual strongly suggest that T 
cells can react to more diverse tumor antigens. According 
to a previous report,29 antigen- specific clonal activation 
increased the TCR diversity of intratumoral T cells. Based 
on this, we initially analyzed TCR clonal diversity among 
Nt5e±, Entpd1±, and Pdcd1± T cells. We observed that T 
cells expressing the Nt5e gene (a gene for CD73) exhib-
ited significantly reduced TCR diversity compared with 
that of Nt5e- negative T cells (online supplemental figure 
2a). The fold change of Nt5e negative T cells to Nt5e 
positive T cells was approximately 6 (figure 3A). Similarly, 
Entpd1 (a gene for CD39) negative T cells had approx-
imately twice as much TCR diversity as Entpd1- positive 
T cells (online supplemental figure 2b). However, Pdcd1 
 on S
eptem












5Kim M, et al. J Immunother Cancer 2021;9:e002503. doi:10.1136/jitc-2021-002503
Open access
Figure 1 Differential cellular composition and lineage of AB680 treated, and programmed cell death protein 1 (PD-1) blocker 
treated and untreated tumor- infiltrating lymphocytes (TILs). (A) Workflow of the study design. Single- cell RNA sequencing 
(scRNA- seq) was conducted with CD45+ TIL cells extracted from three untreated controls, AB680- treated and PD-1 blocking 
antibody- treated tumors. Eight tumors per group were used for fluorescence- activated cell sorting (FACS) analysis. (B) Five 
days after inoculation of CT26 cells (1×106 cells/mouse), AB680 (20 mg/kg) or the PD-1 blocking antibody (20 mg/kg) was 
administered from day 0 to day 15 after initiation of treatment via the intraperitoneal route, as described in the Materials and 
methods section (n=9 mice). Tumor sizes were measured at day 3. (C) At day 15, mice were sacrificed and the extracted tumors 
were weighted. (D) Uniform manifold approximation and projection (UMAP) plot for clusters including all samples. (E) Proportion 
of clusters in each sample. (F) Heatmap representing cluster- specific gene expressions. The yellow color represents high 
expression, and purple represents low expression. (G) Proportions of clusters among the controls, AB680- treated, and PD-1 
blocker treated TILs. The error bar denotes SEM (t- test, *p<0.05, **p<0.05, ***p=0.001). NS, non- significant.
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Figure 2 Distinct T cell subclusters of AB680 treated, and programmed cell death protein 1 (PD-1) blocker treated and 
untreated tumor- infiltrating lymphocytes (TILs). (A) Uniform manifold approximation and projection (UMAP) plot for T cell 
subclusters. (B) UMAP plots for the group- specific distribution of T cells. (C) Heatmap representing cluster- specific gene 
expressions. (D) Heatmap for the expression profile of marker genes (z- score of log2(CPM+1)) used to identify the cell type of 
each subcluster and to determine the degree of depletion. Red and blue colors denote upregulated and downregulated genes, 
respectively. (E) Proportion of clusters in each sample. (F) Box- and- whisker plot comparing the proportion of cells within a T 
cell subcluster effector CD8+ T cell (C9) between the controls and the PD-2 blocker (t- test, *p < 0.05), within MALAT1high Treg T 
cells (C2) between the controls and the PD-2 blocker (t- test, **p = 0.01), and within CD4+ exhausted T cells (C11) between the 
controls and PD-2 blocker (t- test, ***p = 0.001). NS, non- significant.
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Figure 3 T cell receptor (TCR) diversity and distinct transcriptional profiles related to the expression of NT5E, ENTPD1, and 
PDCD1 in T cells. Fold changes of TCR diversity of (A) Nt5e- negative to Nt5e- positive T cells. (B) Entpd1- negative to Entpd1- 
positive T cells, and (C) Pdcd1- negative to Pdcd1- positive T cell in the control, AB680- treated and programmed cell death 
protein 1 (PD-1) blockade- treated intratumoral T cells.(D) TCR diversity among the control, AB680- treated, and PD-1 blocker- 
treated intratumoral T cells. (E) Uniform manifold approximation and projection (UMAP) plot for the expression of Nt5e in T cells. 
(F) Volcano plots for the differentially expressed genes (DEGs) of Nt5e- positive T cells compared with negative T cells. Red and 
blue dots denote upregulated and downregulated DEGs, respectively, with a p value <0.05 and a |ln(FC: fold change)|>0.25. 
(G) UMAP plot for the expression of Entpd1 in T cells. (H) Volcano plots for the DEGs of Entpd1- positive T cells compared with 
the negative T cells. Red and blue dots denote upregulated and downregulated DEGs, respectively, with a p value <0.05 and 
a |ln(FC: fold change)|>0.25. (I) UMAP plot for the expression of Pdcd1 in T cells. (J) Volcano plots for the DEGs of Pdcd1- 
positive T cells compared with negative T cells. Red and blue dots denote upregulated and downregulated DEGs, respectively, 
with a p value <0.05 and a |ln(FC: fold change)|>0.25. (K) Kaplan- Meier plot for overall survival rates between Nt5e high and 
low expression colorectal cancer (CRC) patients. (L) Kaplan- Meier plot for overall survival rates between Entpd1 high and low 
















8 Kim M, et al. J Immunother Cancer 2021;9:e002503. doi:10.1136/jitc-2021-002503
Open access 
(a gene for PD-1 protein)- negative and positive T cells 
did not show significant differences in TCR diversities 
(online supplemental figure 2c). Importantly, there was a 
significant effect in TCR diversities by treatment of PD-1 
blockade (figure 3B,C, online supplemental figure 2b). 
PD-1 blocker significantly increased TCR diversity fold 
change of Entpd1- negative T cells to Entpd1- positive 
T cells (figure 3B) by increasing TCR diversity of PD-1 
blockade- treated Entpd1- negative T cells compared 
with untreated Entpd1- negative T cells (online supple-
mental figure 2b). Conversely, PD-1 blocker significantly 
decreased TCR diversity fold change of Pdcd1- negative T 
cells to Pdcd1- positive T cells (figure 3C) by increasing 
TCR diversity of Pdcd1- positive T cells (online supple-
mental figure 2c). However, there was no significant 
difference in the TCR diversity between the control and 
drug- treated total T cells (figure 3D). We also analyzed 
the percentages of Nt5e, Entpd1, and Pdcd1- positive T 
cells compared with total T cells (online supplemental 
figure 2d). 9.93±1.82, 31.1±6.04 and 54.3±6.98 percentage 
(%) of T cells were Nt5e, Entpd1, and Pdcd1- positive 
T cells in tumors, respectively (online supplemental 
figure 2d). Taken together, PD-1 blockade significantly 
increased TCR diversity of Entpd1- negative T cells and 
Pdcd1- positive T cells suggesting improved antigen- 
specific clonal activation.
Distinct transcriptional profiles related to the expression of 
Nt5e, Entpd1, and Pdcd1 in T cells
To understand the potential biological roles of adenosine 
and PD-1 signaling on T cells, we analyzed the difference 
in full- scale transcription between negative and posi-
tive Nt5e, Entpd1, and Pdcd1 expression in T cells. As 
shown in online supplemental figure 2d, Nt5e was only 
expressed in 9.93±1.82% of intratumoral T cells. It was 
mainly expressed in Treg and CD8+ exhausted T cells 
(figure 3E). To understand the characteristic transcrip-
tional profile of Nt5e- positive T cells, we performed 
DEG analysis of Nt5e- negative T cells and Nt5e- positive 
T cells (figure 3F). We observed significantly upregulated 
levels of Cdc12, Klrd1, and Cd86 in Nt5e- positive T cells 
compared with those in Nt5e- negative T cells (figure 3F). 
AB680 and PD-1 treatments resulted in distinct tran-
scriptional changes in Nt5e- positive T cells (figure 3F). 
Enptd1 was also expressed primarily in Tregs (C2, C4) 
and exhausted T cells (figure 3G). Entpd1 was expressed 
in 31.1%±6.04% of intratumoral T cells (figure 3D). A 
large proportion of genes were differentially regulated in 
Entpd1- positive T cells compared with levels in Entpd1- 
negative T cells (figure 3H). Importantly, AB680 treat-
ment significantly increased the expression of Gzmb, 
Gzmd, Gzmf, Prf1, and Irf8 in Entpd1- positive T cells 
compared with that in the control (figure 3H). Pdcd1 was 
primarily expressed in Tregs and CD8+ exhausted T cells 
(figure 3I), and Pdcd1- positive T cells exhibited differ-
ential expression compared with that observed in Pdcd1- 
negative T cells (figure 3J). AB680 treatment and PD-1 
blockade regulated gene expression in Pdcd1- positive 
T cells through different pathways (figure 3J). Differ-
ential transcription of Nt5e- negative T cells and Nt5e- 
positive T cells was correlated with different biological 
and signaling pathways (online supplemental figure 2e). 
Hypoxia and the glycolysis pathway were significantly 
upregulated in Nt5e- positive T cells compared with levels 
in Nt5e- negative T cells (online supplemental figure 2e). 
Conversely, TNFα signaling via the NF-κB pathway was 
downregulated in Nt5e- positive T cells compared with 
Nt5e- negative T cells (online supplemental figure 2e). 
Importantly, TNFα signaling via the NF-κB pathway was 
also downregulated in both Entpd1- positive T cells and 
Pdcd1- positive T cells (online supplemental figure 2f,g). 
Moreover, glycolysis and hypoxia pathways were also 
significantly upregulated in Entpd1- positive T cells and 
Pdcd1- positive T cells (online supplemental figure 2f,g). 
However, differentially regulated pathways such as the 
complement pathway (only by Entpd1- positive and Pdcd1- 
positive T cells and not by Nt5e- positive T cells) and the 
oxidative phosphorylation pathway (by Pdcd1- positive 
T cells) by Nt5e- positive, Entpd1- positive, and Pdcd1- 
positive T cells were also observed (online supplemental 
figure 2e- g). We also show the frequencies in the form 
of violin plots for NT5e, Entpd1, and Pdcd1 to demon-
strate the proportion of Nt5e, Entpd1, and Pdcd1- postive 
cells in all treatment groups (online supplemental figure 
3). As shown in figure 3K, patients with CRC possessing 
low expression of Nt5e exhibited significantly increased 
overall survival rates compared with those of patients 
with CRC possessing high expression of Nt5e. However, 
the expression level of Entpd1 did not affect the overall 
survival of patients with CRC (figure 3I). Similarly, low 
expression of Pdcd1 did not alter the overall long- term 
survival rates of patients with CRC (figure 3M).
Distinct transcriptional profiles associated with the immune-
exhausted phenotype were observed in AB680-treated and 
PD-1 blocker-treated intratumoral Treg cells
We identified two distinct Treg populations (C2 and 
C4). The proportion of total Tregs (C2+C4) was not 
significantly different among the groups (online supple-
mental figure 4a). However, AB680 and PD-1 blocker 
treatments triggered transcriptional changes in control 
Treg cells (online supplemental figure 4b). Specifi-
cally, two Treg populations (C2 and C4) expressed high 
levels of Foxp3, which is a well- known marker of Tregs30 
(figure 4A). However, DEG analysis of the two Treg popu-
lations revealed significantly upregulated expression of 
Malat1 in the C2 cluster (figure 4B), and this was previ-
ously reported to be associated with Treg differentiation 
from the Th17/Treg precursor.31 We observed that Foxp3 
expression was significantly higher than that in the other T 
cell populations (figure 4A,C). These two Tregs possessed 
distinct transcriptional profiles in regard to genes such as 
Zeb1, Ikzf2, Il2ra, Ctla4, and Il-10 (figures 2D, 4B,C). We 
observed that treatment with AB680 and PD-1 blockers 
altered gene expression in both of the Treg populations 
(figure 4B,C). Importantly, AB680 treatment significantly 
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Figure 4 Treg and CD4+ exhausted T cell subclusters. (A) Uniform manifold approximation and projection (UMAP) plot for 
the expression of the marker gene, Foxp3, which characterizes Treg cell subclusters. (B, C) Volcano plots for the differentially 
expressed genes (DEGs) of Treg cell subclusters 2 and 4, compared with the other clusters. Red and blue dots denote 
upregulated and downregulated DEGs, respectively, with a p value <0.05 and a |ln(FC: fold change)|>0.25. (D) Heatmap for 
the expression profile of marker genes (z- score of log2(CPM+1)) used to identify the cell type of Treg subcluster (C2) and to 
determine the degree of changes in the gene expression caused by the AB680 and programmed cell death protein 1 (PD-1) 
blocker treatment. Red and blue colors denote upregulated and downregulated genes, respectively. (E) Representative dot 
plots show the percentage (%) of CD25+, Foxp3+, and Treg cells from CD4+ T cells extracted from the control, AB680- treated, 
and the PD-1 blocker- treated tumor- infiltrating lymphocytes (TILs) through fluorescence- activated cell sorting (FACS) analysis. 
(F) Graphical representation of the percentages (%) of Treg cells from CD4+ T cells extracted from eight different control TILs, 
AB680- treated TILs, and PD-1 blocker- treated TILs. Short horizontal lines indicate the means (t- test, NS, non- significant; 
*p<0.05; **p<0.01). (G) UMAP plot for the expression of marker genes, IKZF2 and TOX, to characterize exhausted T- cell 
subclusters. (H) Heatmap for the expressions of marker genes used to identify the cell type of each subcluster. Red and blue 
colors denote upregulated and downregulated genes, respectively, which were used to determine the degree of changes by the 
AB680 and PD-1 blocker treatment. (I) Volcano plots for DEGs of exhausted CD4+ T cell subcluster (C11) compared with those 
of the other clusters. NS, non- significant.
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upregulated the effector molecule genes Gzma, Gzmd, 
Gzme, and Nkg7 in Tregs (C2), and PD-1 blocker treat-
ment did not upregulate these genes (figure 4D). In 
regard to the cytokine production profiles, Ab680 treat-
ment resulted in increased Ifng (figure 4d). Furthermore, 
AB680 treatment downregulated the expression levels 
of Entpd1, Havcr2, and Zeb1 (figure 4d) and the PD-1 
blocker significantly upregulated Treg markers such as 
Malt1, Cd274, and Ikzf2 in Tregs (C2) (figure 4B- D). 
Nevertheless, AB680 did not cause changes in the propor-
tions of different Tregs (figure 4F), and AB680 treat-
ment decreased the expression of immune- exhausted 
phenotype- associated genes in intratumoral Treg cells 
(figure 4D) to a greater extent than did PD-1 blockade. 
To confirm our findings, we analyzed Treg populations 
within tumors using flow cytometry (figure 4E). As 
presented in figure 3E, we confirmed that Foxp3+ Treg 
cells were significantly reduced in PD-1 blocker- treated 
tumors. Although AB680 treatment significantly down-
regulated the proportion of Foxp3+ Treg cells, its effect 
on Treg proportion was significantly weaker than was that 
induced by PD-1 blockade (figure 4E,F). Furthermore, we 
confirmed a significantly upregulated expression of inter-
feron-γ (IFNγ) and granzyme B (GzB) in Treg cells in the 
AB680- treated group compared with levels in the control 
group according to flow cytometry analysis, and this 
was not observed after treatment with the PD-1 blocker 
(figure 4F).
Distinct transcriptional profiles associated with the immune-
exhausted phenotype were observed in AB680-treated and 
PD-1 blocker-treated intratumoral CD4+ and CD8+ Tex cells
As shown in figure 4G, one CD4+ Tex cell population 
(C11) and six CD8+ Tex cell populations (C0, C1, C5, C6, 
C8, and C10) expressed high levels of the transcription 
factors Ikzf2 and Tox, both of which are well- known genes 
associated with T cell exhaustion.32 33 Additionally, DEG 
analysis of the CD4+ Tex population revealed the pres-
ence of significantly upregulated inhibitory molecules 
such as Ikzf2, Lag3, Havcr2, and Entpd1 in the C11 cluster 
(figure 4H,I).34 Our volcano blot (figure 4I) revealed that 
gene expression was significantly altered in response to 
AB680 treatment and PD-1 blockade in CD4+ Tex cells 
(C11). Specifically, significant upregulation of Gzma 
and Gzmd was observed in the AB680- treated CD4+ Tex 
cells (C11) and not in cells treated with the PD-1 blocker 
(figure 4G,I). In our study, we observed that Cx3cr1 was 
highly expressed in six CD8+ Tex cell populations (C0, C1, 
C5, C6, C8, and C10) (figure 5A). The six CD8+ Tex cell 
populations exhibited high expression of Nt5e, Pdcd1, 
Foxp3, Ikzf2, Havcr2, and Entpd1, all of which are known 
for their immunosuppressive roles (figure 2D).34–36 
AB680 treatment and PD-1 blockade reduced the expres-
sion levels of Pdcd1, Foxp3, and Entpd1 compared with 
those of the control CD8+ Tex cells (figure 5B). Neverthe-
less, we found that AB680- treated CD8+ Tex cells upreg-
ulated the expression of Ifng, while the PD-1 blocker did 
not (figure 5B). Furthermore, AB680- treated CD8+ Tex 
cells exhibited decreased expression of Lag3 and Havcr2, 
while the PD-1 blocker- treated cells did not (figure 5B). 
To confirm our results, we analyzed the expression 
pattern of CX3CR1 in CD8+ T cells using flow cytom-
etry (figure 5C). Notably, inhibitory molecules such as 
LAG3 and HACR2 (also known as TIM3) were highly 
expressed in CX3CR1+ CD8+ TILs derived from control 
mice (figure 5C). Furthermore, we confirmed significant 
upregulation of GzB and IFNγ in AB680- treated CD8+ Tex 
cells through the use of flow cytometry (figure 5D). These 
results are consistent with our findings that were obtained 
using scRNA- seq (figure 5B).
AB680 triggered the effector function of exhausted CD8+ T 
cells in a limited manner, while PD-1 blockade did not affect 
this process
As shown in figure 2D, one CD8+ effector T cell popu-
lation (C9) was identified that possessed relatively high 
expression levels of Gzmb, Gzma, Ifng, and CD69 and low 
expression levels of Tox, Ikzf2, Foxp3, and Havcr2. There 
was no significant proportional change in the C9 cluster 
of AB680- treated TILs; however, the PD-1 blocker signifi-
cantly increased the proportion of C9 clusters (figure 2F). 
There was a transcriptional change in the regulation of 
gene expression, including the expression of Gzme, Irf8, 
TNFRSF9 (also known as 41- BB), and Icos, after AB680 
exposure (figure 5F,G). Importantly, this transcriptional 
change that was triggered by AB680 was distinct from 
that triggered by the PD-1 blocker (figure 5F). Further-
more, we analyzed the proportion of CD69+ CD8+ T cells 
using flow cytometry (figure 5H,I). Notably, we observed 
that CD69, a marker protein for TCR signaling- mediated 
activation of T cells,37 was increased in AB680- treated 
and PD-1 blocker- treated CD8+ T cells, thus highlighting 
their role to at least partially activate exhausted CD8+ T 
cells. Importantly, we observed a relatively low level of 
CD69 expression in AB680- treated CD8+ effector T cell 
population (C9) compared with that in the PD-1 blocker- 
treated group (figure 5H,I). Interestingly, AB680 treat-
ment triggered the expression of Tox, a process that is 
well known to be indicative of T cell exhaustion,32 33 in 
the CD8+ effector T cell population (C9). This suggested 
that AB680 treatment, and not PD-1 blockade, triggered 
the effector function of exhausted CD8+ T cells. However, 
we observed that the expression of Gzmd and Gzme 
was significantly increased in AB680 blocker- treated 
effector CD8+ T cells and that only Gzme was significantly 
increased in PD-1 blocker- treated effector CD8+ T cells, 
thus suggesting a distinct immune activation mechanism 
of AB680 (figure 5J).
Partial depletion of M2 macrophages was observed in PD-1 
blocker-treated TILs, and enrichment of inflammatory M1 
macrophages was observed in AB680-treated TILs according 
to a reclustering analysis of the myeloid lineage cells
To understand the changes in the cellular composition, 
lineage, and interaction of myeloid cells from tumors 
in the presence or absence of AB680 and PD-1 blocker 
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Figure 5 CD8+ exhausted T cell and effector CD8+ T cell subclusters. (A) Uniform manifold approximation and projection 
(UMAP) plot for the expression of the marker gene, CX3CR1, characterizing CD8+- exhausted T cell subclusters. (B) Heatmap 
for the expression profile of marker genes (z- score of log2(CPM+1)) used to identify the cell type of CD8+-exhausted T cells (C0, 
1, 5, 6, 8, 10) and to determine the degree of changes in gene expression by the AB680 and programmed cell death protein 1 
(PD-1) blocker treatment. Red and blue colors denote upregulated and downregulated genes, respectively. (C) Representative 
dot plots show the percentage (%) of CX3CR1+ CD8+ T cells from T cells and their expressions of Lag3 and Havcr2 extracted 
from control tumor- infiltrating lymphocytes (TILs) through fluorescence- activated cell sorting (FACS) analysis. (D) Graphical 
representation of the percentages (%) of CX3CR1+ Lag+ CD8+ T cells, GzB+ CX3CR1+ CD8+ T cells, and IFNγ+ CX3CR1+ CD8+ 
T cells extracted from control TILs, AB680- treated TILs, and PD-1 blocker- treated TILs. Short horizontal lines indicate the 
means (t- test, NS, non- significant; *p<0.05; ***p<0.001). (E) UMAP plot for the expression of marker genes, Gzmb and CD69, 
characterizing effector CD8+ T cell subclusters. (F) Volcano plots for the DEGs of the effector CD8+ T cell subcluster (C9) 
compared with other clusters. Red and blue dots denote upregulated and downregulated DEGs, respectively, with a p value 
<0.05 and a |ln(FC: fold change)|>0.25. (G) Heatmap for the expression profiles of marker genes (z- score of log2(CPM+1)) used 
to identify the cell type of the effector CD8+ T cell subcluster (C9) and to determine the degree of changes in the AB680 and 
PD-1 blocker treatments. Red and blue colors denote upregulated and downregulated genes, respectively. (H) Representative 
histograms show the Mean fluorescence of intensity(MFI) for CD69 expressed in CD8+ T cells extracted from the control, 
AB680- treated, and PD-1 blocker treated TILs through FACS analysis. (I) Graphical representation of the percentages (%) of 
CD69+ CD8+ T cells extracted from control TILs, AB680- treated TILs and PD-1 blocker- treated TILs. Short horizontal lines 
indicate the means (t- test, NS, non- significant; *p<0.05; **p<0.01).
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treatment, reclustering analysis of the myeloid cells was 
used to identify nine myeloid cell subclusters that included 
three M1 macrophages (C0, C2, and C6), two monocytes 
(C7 and C9), three M2 macrophages (C3, C4, and C8), 
and two dendritic cells (DCs) (C1 and C5) (figure 6A). 
We identified subclusters of myeloid cells possessing an 
expression pattern of major myeloid cell lineage markers 
with a similar diversity of subclusters in each tumor 
(figure 6B,C, online supplemental figure 5). Based on our 
trajectory analysis, three different directions of cellular 
differentiation were defined (online supplemental figure 
6a). One direction was from monocytes (C7, C9) to M1 
macrophages (C0, C2, C6) and the other was from mono-
cytes (C7, C9) to M2 macrophages (C3, C4, C8) and to 
DCs (C1, C5) (figure 6A). We also determined the expres-
sion patterns of important genes that can be used for the 
identification of myeloid cell subclusters (figure 6D). 
Specifically, we determined that Cx3cr1 was limited to 
M2 macrophages and DCs (online supplemental figure 
4a). As shown in figure 6D, we observed that several genes 
such as Nt5e, Clec10a, Csf1, Tlr2, and Ccr2 were expressed 
in limited amounts. Thus, we identified M2 macrophage 
subclusters that consisted of Nt5e+/Cx3xr1high/Csfhigh M2 
(C3) and Clec10a+/Cx3cr1high/CD163high M2 (C8) macro-
phages (figure 6F). Although the diversity of myeloid cell 
subclusters was similar among the control and the two 
treated groups (figure 6B), we observed that one of the 
M1 macrophages (C0) was significantly increased in the 
AB680- treated tumors compared with that in the control 
(figure 6E). Additionally, another M1 macrophage 
cluster (C6) was increased in the AB680- treated tumor 
compared with that in the control with a p value=0.0757 
(figure 6E). However, AB680 treatment did not affect the 
proportion of M2 cells (figure 6F, online supplemental 
figure 6b). Conversely, PD-1 blockade significantly down-
regulated the proportion of M2 macrophages (C3), while 
it did not affect M1 macrophages. Taken together, AB680 
treatment and PD-1 blockade differentially regulated the 
proportion of myeloid cells in tumors. Notably, AB680 
and PD-1 differentially regulated gene expression in 
myeloid cells (online supplemental figure a- c). As shown 
in online supplemental figure 7a, we observed that the 
AB680- treated Tlr2+ M1 macrophages (C0) were signifi-
cantly upregulated for Gzma, Irf7, and Ly6c1, while PD-1 
blocker- treated Tlr2+ M1 macrophages (C0) were signifi-
cantly upregulated for the expression of Malt1, Btg2, and 
Cxcl9 (online supplemental figure 7a). Similarly, AB680 
significantly increased the expression of Gzma in Nt5e+ 
M2 macrophages (C3) and Fcgr1high macrophages (C6) 
(online supplemental figure 7b,c). Furthermore, AB680 
treatment downregulated the expression of S100a8 in 
Tlr2+ M1 macrophages (C0), Nt5e+ M2 macrophages 
(C3), and Fcgr1high macrophages (C6) (online supple-
mental figure 7a- c).
Distinct immune-stimulating intercellular interactions 
between AB680-treated and PD-1 blocker-treated T cells and 
macrophages
Next, to gain insight into the differential interactions 
among Treg (C2), CD8+ Tex, M1 macrophages (C2), 
and M2 macrophages (C3) treated with AB680 and the 
PD-1 blocker, we investigated the crosstalk between the 
macrophage clusters (C0 and C3) and T cells using 
cellphoneDB.24 In regard to the interaction between 
M2 (C3) and Treg cells (C2), the predicted interaction 
between Ereg on Treg cells (C2) and Egfr from M2 
macrophages (C3) was more prominent in AB680- treated 
tumors than it was in the controls (online supplemental 
figure 8a). But PD-1 did not affect those interaction 
(online supplemental figure 8a). However, PD-1 did not 
affect these interactions (online supplemental figure 7a). 
Conversely, the predicted interaction between Ephb2 on 
Treg cells (C2) and Epna5 from M2 macrophages (C3) 
was more prominent in PD-1- treated tumors than it was 
in the controls (online supplemental figure 8a). For the 
interaction between M1 (C2) and Treg cells (C2), the 
predicted interaction between IL-6 on Treg cells (C2) 
and Hrh1 from M1 macrophages (C2) was more promi-
nent in AB680- treated tumors than it was in the controls 
(online supplemental figure 8b). Importantly, interac-
tions between Tgfb2 on Treg (C2) and Tgfbeta receptors 
1 and 2 on M1 macrophages (C2) were commonly absent 
in both AB680- treated and PD-1 blocker- treated tumors 
(online supplemental figure 7b). In regard to the inter-
action between M1 (C2) and CD8+ Tex cells (C0, 1, 5, 6, 
8, and 10), the interactions between Plxnb3 (plexin B3), 
Jag2, and Pgf on M1 macrophages and Sema5a (Sema-
phorin 7a), Notch2, and Flt1 on CD8+ Tex cells became 
undetectable (online supplemental figure 8c).
The anticancer effect of AB680 treatment and PD-1 blockade 
in the in vivo AOM/DSS model
To understand the effect of AB680 and PD-1 blockers 
on the colitis- associated cancer mouse model, we admin-
istered AB680 and PD-1 blocker for 21 days after the 
third cycle of DSS treatment. To analyze the anticancer 
effects, we measured the diameters of tumors in the large 
intestine of mice (figure 7A). As shown in figure 7B, the 
average diameters for 35 tumors derived from eight mice 
in the control group (AOM/DSS), 18 tumors from eight 
mice in the AB680 group (AOM/DSS+AB680), 27 tumors 
from eight mice in the PD-1 group (AOM/DSS+PD-
1), and 14 tumors from eight mice in the AB680+PD-1 
group (AOM/DSS+AB680+PD-1) were 42.525±8.42 mm, 
37.45±5.08 mm, 38.84±10.22 mm, and 35.2±4.75 mm, 
respectively. The tumor diameters of the AB680+PD-1 
group were significantly reduced compared with those 
of the control group (figure 7B). The number of tumors 
per mouse in the AB680 and AB680+PD-1 groups was also 
significantly reduced compared with that in the control 
group (figure 7C). To understand the immunological 
changes in the large intestine, we analyzed CD4+ T cells, 
CD8+ T cells, and Tregs (figure 7D). Notably, AOM/DSS 
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Figure 6 Myeloid cell subclusters. (A) Uniform manifold approximation and projection (UMAP) plot for myeloid cell subclusters. 
(B) Proportion of clusters in each sample. (C) Heatmap representing cluster- specific gene expressions. (D) Heatmap for the 
expression profile of marker genes (z- score of log2(CPM+1)) used to identify the cell type of each subcluster and to determine 
the degree of depletion. Red and blue colors denote upregulated and downregulated genes, respectively. (E) Box- and- whisker 
plot comparing the proportion of cells within the myeloid cell M1 macrophages (C0) with the controls and AB680, between 
the controls and the PD-2 blocker (t- test, *p = 0.05). (F) Box- and- whisker plot comparing the proportion of cells within M2 
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Figure 7 The effect of AB680 and programmed cell death protein 1 (PD-1) blockade on the in vivo AOM- DSS colorectal 
cancer (CRC) model. After sacrifice of mice as described in the Materials and methods section, (A) representative images for 
tumors in large intestines of mice for the AOM/DSS- induced control (n=8), AOM/DSS+AB680 (10 mg/kg) treated (n=8), AOM/
DSS+PD-1 blockade (10 mg/kg) treated (n=8) and AOM/DSS+AB680 (10 mg/kg)+PD-1 blockade (10 mg/kg) treated group (n=8). 
(B) The diameters of all tumors in large intestines of mice for each group. (C) The number of tumors per mouse were measured 
for each group. Data are presented as mean ± SEM (t- test, NS, non- significant; *p<0.05; **p<0.01). (D) Percentages of CD4+ T 
cells and CD8+ T cells and the percentages of CD4+ Foxp3+ Tregs of large intestinal tissues from healthy and AOM- DSS murine 
models with or without AB680 or PD-1 blocker treatment. These results are representative from all independent experiments 
(n=8 per each group). The graphical results show (E) the percentages (%) of CD4+ Foxp3+ Treg per total T cells and (F) the 
percentages (%) of GzB+ CD8+ T cells of large intestinal tissues. Data are presented as mean ± SEM (t- test, NS, non- significant; 
***p<0.001). (G) The histograms show the proliferating CD8+ T cells in the in vitro culture with or without ATP (20 µM) and AB680 
(0.5 and 20 µM). These results are representative from three independent experiments. (H) The representative histograms show 
the mean fluorescence of intensity (MFI) for CD73 expression level of CD8+ T cells in the in vitro culture with or without ATP 
(20 µM) and AB680 (20 µM). These results are representative from three independent experiments. (I) The graphical result shows 
the percentages (%) of IFNγ+ CD8+ T cells after the in vitro culture with or without ATP (20 µM) and AB680 (0.5 and 20 µM) (n=6). 
Data are presented as mean±SEM (t- test, **p<0.01; ***p<0.001).
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treatment triggered a robust increase in CD4+ T cells and 
CD4+ Foxp3+ Tregs in the large intestine (figure 7D). 
These immunological changes could be altered by PD-1 
blockade and not by AB680 (figure 7D,E). Conversely, 
GzB+ CD8+ T cells were significantly reduced in AOM/
DSS mice compared with numbers in healthy controls 
(figure 7F). The downregulated GzB+ CD8+ T cells were 
significantly recovered in response to AB680 treatment 
and not by PD-1 treatment (figure 7F). These results were 
consistent with our data from the CRC- cell- line- harboring 
in vivo tumor mouse model.
AB680 directly boosted in vitro T cell proliferation and IFNγ 
production
To verify the direct effect of AB680 on the regulation of 
proliferation and IFNγ production in CD8+ T cells, we 
purified human T cells and tested the effect of AB680 on T 
cell proliferation and IFNγ production within the in vitro 
culture (figure 7G,I). First, we showed the similar levels 
of CD73 expression on control (untreated), 20 µM APT 
treated and 20 µM ATP plus AB680- treated human CD8+ T 
cells, which were isolated from human peripheral blood, 
suggesting ATP and AB680 do not affect the expression of 
CD73 on human CD8+ T cells (figure 7H). Notably, 20 µM 
of extracellular ATP significantly downregulated prolif-
eration of CD8+ T cells (figure 7G). It should be caused 
by conversion of extracellular ATP to adenosine. Those 
conversion could be inhibited by treatment of AB680, 
resulting in the recovery of T cell proliferation similar 
level to positive control (untreated group) (figure 7G). 
Furthermore, we measured IFNγ production from CD8+ 
T cells through flow cytometry analysis (figure 7I). For 
those purpose, we permeabilized and stained the fixed 
CD8+ T cells with anti- IFNγ mAb for analysis. Importantly, 
we found that ATP treatment significantly reduced IFNγ 
producing CD8+ T cells compared with untreated group 
(figure 7I). However, AB680 treatment could increase 
IFNγ producing CD8+ T cells compared ATP- treated 
CD8+ T cells (figure 7I). Those results strongly suggest 
that AB680 has a potent direct effect to boost CD8+ T cell 
function under the microenvironment equipped with 
enriched extracellular ATP or adenosine.
DISCUSSION
The tumorigenic mechanism of extracellular adenosine 
has been widely studied in a number of solid tumors, 
including ovarian cancer38 and non- small- cell lung 
cancer.15 Recently, the significance of adenosine in 
gastrointestinal cancers, including CRC,39 has also been 
highlighted. Thus, novel drug candidates targeting 
adenosine- related mechanisms such as ciforadenant 
(previously known as CPI-444) and AB-680 that act as 
A2AR antagonists and CD73 inhibitors, respectively, 
have been developed.28 40 In humans, CD4+CD25high-
FOXP3+ regulatory T cells (Treg) are predominantly 
CD39+,41 while CD39 and CD73 are overexpressed in 
tumor- associated macrophages (TAMs)42 and tumor 
cells.43 These previous reports are consistent with our 
results (figures 3G and 7C). The abundance of TAMs is 
correlated with poor prognosis in various tumors, ask 
they can induce resistance to antitumor treatments (ie, 
chemotherapy, anti- PD1, and others).44 45 Additionally, 
the polarization of M2 macrophages is stimulated by 
adenosine. In this study, we observed that the increase 
in the proportion of Ccr2+ Tlr2high M1 macrophages was 
one of the major mechanisms boosting the anticancer 
immunity of AB680 (figure 6F). These results are consis-
tent with those of previous studies46 47 that suggested 
the importance of M1 macrophages for anticancer 
immunity. In this study, we confirmed that Cx3cr1 was 
primarily expressed in DC and M2 macrophages, while 
Ccr2 was predominantly expressed in M1 macrophages 
(figure 6D,E, online supplemental figure 5b). This is 
consistent with the results of other previous studies.48 
Conversely, PD-1 blockade significantly downregulated 
the proportion of Cx3cr1high/Csf1high/Nt5e+ M2 macro-
phages (C3), and it did not affect M1 macrophages. 
Taken together, our data strongly suggest that the regula-
tion of the M1/M2 macrophage proportion represents a 
major mechanism of action of AB680 and PD-1 blockers 
in regard to boosting their anticancer effects.
Next, we determined that the majority of intratumoral 
T cells were Tex and Treg cells (figure 2A, E). In this 
study, PD-1 blocker treatment exhibited a potent effect 
in reducing the numbers of Malat1high Treg and CD4+ Tex 
cells (figure 2E). The compositional regulation of PD-1 
blocker treatment may provide an important benefit in 
regard to tumor regression due to its ability to increase 
TCR diversity in some portions of T cells (figure 3B,C, 
online supplemental figure 2b,c). Interestingly, PD-1 
blocker treatment selectively increased the TCR diver-
sities of entpd1- negative T cells and Pdcd1- positive T 
cells (online supplemental figure 2b,c). This may be 
explained by the compensatory immunoregulatory 
mechanism of PD-1 that functions to suppress the TCR 
diversity signal in addition to the adenosine signal. There-
fore, extracellular ATP/adenosine hampers the efficacy 
of anti- PD-1 immune checkpoint blockade in a manner 
that is likely due to a compensatory immunoregulatory 
mechanism.49 50 A subset of patients with melanoma 
undergoing anti- PD1 immunotherapy exhibited upreg-
ulation of tumor- derived CD73 expression.51 Moreover, 
a recent clinical trial examining the use of ciforadenant 
plus atezolizumab (an anti- PD- L1 antibody) for treating 
renal cell cancer revealed that the combination therapy 
improved efficacy.52 The patients in this study were 
primarily resistant or refractory to anti- PD-1/PD- L1 ther-
apies and represented PD- L1- negative tumors, thus indi-
cating the complementary roles of adenosine and PD- L1 
within the tumor microenvironment. However, to date, 
there is still a poor understanding of how extracellular 
adenosine limits the effectiveness of PD-1 blockers. Our 
data strongly support the previous assumption that ATP/
adenosine could suppress intratumoral immune cells in 
a different manner compared with that of PD- L1/PD-1, 
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and we described this in our current study. Thus, inhibi-
tion of ATP/adenosine signaling may represent one of 
the most efficient and synergistic therapeutic approaches 
in combination with PD-1 blockers for the treatment of 
CRC. To summarize, our report detailing the applicability 
of the CD73 inhibitor AB680 and its mode of action in 
the context of CRC may provide novel insight for under-
standing its potential and efficacy in the treatment of 
CRC. Moreover, our study may aid in the development 
of a novel treatment method for patients with refractory 
CRC who do not respond to existing chemotherapy anti-
cancer drugs and PD-1 antagonists.
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